NCT00298350View on ClinicalTrials.gov

Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

PHASE2CompletedINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

July 31, 2007

Conditions
HIVHIV-1Human Immunodeficiency Virus
Interventions
DRUG

GS-9137 - A Novel HIV-1 Integrase Inhibitor

Trial Locations (54)

10016

New York

11030

Manhasset

17033

Hershey

19107

Philadelphia

20037

Washington D.C.

21205

Baltimore

23666

Hampton

28078

Huntersville

29206

Columbia

30033

Decatur

31201

Macon

32803

Orlando

32960

Vero Beach

33136

Miami

33169

North Miami Beach

33308

Fort Lauderdale

33408

North Palm Beach

33462

Atlantis

33602

Tampa

34239

Sarasota

44106

Cleveland

48202

Detroit

53226

Milwaukee

60657

Chicago

60813

Long Beach

63108

St Louis

72207

Little Rock

75204

Dallas

77030

Houston

80220

Denver

85006

Phoenix

87505

Santa Fe

89074

Henderson

90033

Los Angeles

90211

Beverly Hills

90502

Torrance

92103

San Diego

92663

Newport Beach

92708

Fountain Valley

94086

Sunnyvale

94110

San Francisco

94609

Oakland

98101

Seattle

98405

Tacoma

94305-5107

Stanford

06851

Norwalk

02215-3318

Boston

01107

Springfield

08844

Hillsborough

12208-3479

Albany

27157-1042

Winston-Salem

22003-7313

Annandale

00921-3201

San Juan

00909

Santurce

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT00298350 - Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART. | Biotech Hunter | Biotech Hunter